Breast Cancer Therapies – Discover From 2016 What Revenues Are Possible Are you interested in the breast cancer drug market’s future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects.
Visiongain’s study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anti cancer drugs can achieve. See what is possible in that leading drugs market.
Please read on now to explore that industry and see what future revenue its expanding market could generate.
Original analysis to benefit your research, plans, decisions and proposals The future holds great potential for pharma companies treating breast cancer. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2016, revenues and other progress that are possible.
Besides revenue forecasting to 2026, our new work shows you recent results, sales growth rates and market shares. You assess research and development too. And in that report you gain 93 tables, 49 charts and interviews with two companies.
Our study’s purpose is to help your research, analyses and decisions on breast cancer treatments, benefiting your authority and reputation for commercial insight. That way you can stay ahead in knowledge to help you stand out and succeed.
Although no single report covers everything, the following sections show how our new investigation benefits your work.
Forecasts covering the overall world market and segments for treating breast cancer Discover in our new analysis revenue predictions to 2026 for breast cancer submarkets at world level. See what is possible for these four therapeutic classes: • Monoclonal antibodies (mAbs) • Chemotherapy and hormone therapy • Kinase inhibitors • Other medicines.
Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors’ actions and outlooks. Discover, from 2016, what is possible.
With a rising incidence of breast cancer worldwide and large patient populations, the demand for better treatments will continue to bolster that industry and market. Explore prospects for patients, healthcare providers and pharma companies.
Our new investigation also shows you revenue predications by product, exploring how those agents can succeed.
Forecasts for leading drugs – what sales are possible? How will individual breast cancer medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of these nine leading brands: • Herceptin (trastuzumab), Roche • Perjeta (pertuzumab), Roche • Afinitor (everolimus), Novartis • Faslodex (fulvestrant), AstraZeneca • Ibrance (palbociclib), Pfizer • Avastin (bevacizumab), Roche • Kadcyla (ado-trastuzumab emtansine), Roche • Femara (letrozole), Novartis • Abraxane (paclitaxel Protein-Bound), Celgene
Our investigation also forecasts sales of two biosimilar drug classes: trastuzumab and bevacizumab.
In that study you see how high revenues can go, finding products and years with highest predicted sales. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.
Discover what the future holds for treating breast cancer. Our work also shows you geographical sales predictions.
National markets – what outlooks for those anticancer drug revenues? Advances in the biopharma industry expand the range and use of medicines to treat breast cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2026 for 11 leading national markets: • The United States • Japan • Germany, France, Italy, the United Kingdom and Spain (EU5 countries) • Brazil, Russia, India and China (BRIC group)
With our study you assess regions with highest revenues and potential sales growth. Explore outlooks for treating breast cancers, including discussions of patients’ and healthcare providers’ needs.
You also examine developments leading to novel and improved breast cancer medications.
R&D for those anticancer medicines – trends, innovations and progress In our study you investigate research and development on breast cancer. You examine advances in oncology, assessing clinical trials and seeing what they show.
Our survey discusses 18 medicines in development for breast cancer, including these agents: • Taselisib (GDC-0032/RG7604), Roche • Atezolizumab (MPDL3280A/RG7446), Roche • Buparlisib (BKM120), Novartis • Alpelisib (BYL719), Novartis • Ribociclib (LEE011), Novartis • AZD5363, AstraZeneca • MEDI-573, AstraZeneca and MedImmune • Abemaciclib (LY2835219), Eli Lilly • Veliparib (ABT-888), AbbVie.
Our work shows you what is possible. R&D gains momentum from rising disease prevalence and other forces making treatments for that common cancer more widely used. See how demand increases.
Events and changes affecting companies treating breast cancer Our study explains forces shaping the industry and market, letting you explore what is happening from 2016: • Extension of drugs’ use – gaining approval for a wider indication range • Existing products and their futures – leading pharma companies’ strategies • The race to gain drug approvals, especially from the FDA and EMA • Progress in clinical trials – finding the most promising medicines • Patent challenges – protecting intellectual property in a competitive market – the rise of generics and biosimilars • Combination therapies and other developments for biological drugs • Cost challenges – pricing and reimbursement, including proving value and clinical superiority.
You also gain SWOT analysis, assessing what drives and restrains that expanding anticancer drugs industry. See what shapes its market from 2016.
Our work shows what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating breast cancer.
Overall 2020 market value – what revenues are possible? Our work predicts the world market for those drugs will reach $19.96bn in 2020. That industry will achieve revenue expansion from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.
For breast cancer therapies you assess leading drug developers, producers and marketers serving those therapeutic needs.
In our study you also discover interviews with CASI Pharmaceuticals and MacroGenics. See what the future holds for companies, exploring what they say and do, as well as their commercial prospects.
7 main ways Breast Cancer Drugs 2016-2026 helps your work Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge for your plans, decisions and proposals: • Revenues for breast cancer drugs to 2026 – assess that overall world market’s potential, seeing scope for investments, production and marketing • Submarket revenues to 2026 covering 4 therapeutic segments – explore treatment categories, seeing their sales outlooks from 2016 • Leading products’ sales to 2026 – discover predicted revenues of 9 top drugs, assessing how well those medicines can compete and succeed • National market predictions to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for demand, sales and growth • Research and development – see progress, trends and prospects in that oncological R&D, finding technological, clinical and commercial possibilities • Companies, news and opinions – examine participants in that rising market, gaining insight to help you stay ahead and benefit your influence • Analysis of what stimulates and restrains that market – assess challenges and strengths, helping you compete and gain advantages.
That analysis, by our in-house team in the UK, gives knowledge to benefit your research and plans. It shows data you find nowhere else. Gain information leading companies depend on.
Predictions for treating breast cancer – gain data to help you stay ahead With our independent study you explore products, companies, progress and possibilities. Discover the best opportunities and assess commercial potentials.
Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort. Also benefit your plans, decisions, presentations, proposals and authority.
Our investigation shows you data, trends, opportunities and forecasts for that expanding anticancer market. Avoid missing out. Instead please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease
3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026
4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics
5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market
6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
Table 4.3 Clinical Investigation of Kadcyla and Perjeta in Wider BC Indications, 2016
Table 4.4 Buparlisib (BKM120) Selected Ongoing and Completed BC Clinical Trials, 2016
Table 4.5 Alpelisib (BYL719) Selected BC Clinical Trials, 2016
Table 4.6 Ribociclib (LEE011) Selected BC Clinical Trials, 2016
Table 4.7 AZD5363: Selected BC Ongoing Clinical Trials, 2016
Table 4.8 Abemaciclib (LY2835219): Selected Ongoing BC Clinical Trials, 2016
Table 4.9 Veliparib (ABT-888): Selected BC Clinical Trials, 2016
Table 4.10 Ganetespib Selected BC Clinical Trials, 2016
Table 4.11 MM-302 BC Clinical Trials, 2016
Table 4.12 Neratinib (PB272) Selected BC Clinical Trials, 2016
Table 4.13 Margetuximab Recent and Ongoing Clinical Trials, 2016
Table 5.1 Global Breast Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2020
Table 5.2 Global Breast Cancer Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2021-2026
Table 6.1 Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.2 Therapeutic Segments within the Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.3 mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.4 mAbs Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.5 Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.6 Chemotherapy and Hormone Therapy Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.7 Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.8 Kinase Inhibitor Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.9 ‘Others’ Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.10 ‘Others’ Segment of the Breast Cancer Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.11 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.12 Regional Forecasts for the Global Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.13 US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.14 US Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.15 German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.16 German Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.17 French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.18 French Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.19 Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.20 Italian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.21 UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.22 UK Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.23 Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.24 Spanish Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.25 Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.26 Japanese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.27 Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.28 Chinese Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.29 Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.30 Brazilian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.31 Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.32 Russian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
Table 6.33 Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2014-2020
Table 6.34 Indian Breast Cancer Drugs Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
List of Figures
Figure 3.1 Total Herceptin Revenues 2010-2015: Revenues ($bn)
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
